Abstract：
BACKGROUND: Neglected parasitic diseases constitute a broad spectrum of clinical conditions that, in the chronic phase, lack effective therapies for the target population. The utilization of vaccines based on liposomal nanocarrier systems is emerging, thereby enhancing clinical outcomes in various comorbidities. Consequently, this study aims to assess the immunological activity induced by liposomal nanocarriers against neglected parasitic diseases.
METHODS: For the review, the Pubmed, Embase, and Lilacs databases were used using the descriptors vaccine, parasite, and liposome. The following inclusion criteria were adopted: in vivo and in vitro experimental articles. As exclusion criteria: book chapters, editorials, literature reviews and duplicate articles found during the database search.
RESULTS: A total of 226 articles were identified, from which 34 were selected for review. The primary diseases identified included Babesia bovis, Entamoeba histolytica, Leishmania braziliensis, Leishmania donovani, Leishmania major, Leishmania infantum, Plasmodium falciparum, Plasmodium chabaudi, Plasmodium chabaudi, Plasmodium yoelii, Toxoplasma gondii and Trypanosoma cruzi. An elevation in cytokines such as GM-CSF, MCP-1, INF-γ, TNF-α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-17 was observed in the studies evaluated regarding the parasitic diseases. Furthermore, cytokines such as IL-4, IL-10, and TGF-β were diminished with the administration of the vaccine systems in those studies.
CONCLUSIONS: Therefore, the administration of liposomal nanovaccine systems can effectively ameliorate the clinical condition of patients by modulating their immunological profile.
METHODS: For the review, the Pubmed, Embase, and Lilacs databases were used using the descriptors vaccine, parasite, and liposome. The following inclusion criteria were adopted: in vivo and in vitro experimental articles. As exclusion criteria: book chapters, editorials, literature reviews and duplicate articles found during the database search.
RESULTS: A total of 226 articles were identified, from which 34 were selected for review. The primary diseases identified included Babesia bovis, Entamoeba histolytica, Leishmania braziliensis, Leishmania donovani, Leishmania major, Leishmania infantum, Plasmodium falciparum, Plasmodium chabaudi, Plasmodium chabaudi, Plasmodium yoelii, Toxoplasma gondii and Trypanosoma cruzi. An elevation in cytokines such as GM-CSF, MCP-1, INF-γ, TNF-α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IL-17 was observed in the studies evaluated regarding the parasitic diseases. Furthermore, cytokines such as IL-4, IL-10, and TGF-β were diminished with the administration of the vaccine systems in those studies.
CONCLUSIONS: Therefore, the administration of liposomal nanovaccine systems can effectively ameliorate the clinical condition of patients by modulating their immunological profile.
摘要：
背景：被忽视的寄生虫病构成了广泛的临床病症，在慢性期，缺乏针对目标人群的有效疗法。基于脂质体纳米载体系统的疫苗的利用正在兴起，从而提高各种合并症的临床结果。因此,本研究旨在评估脂质体纳米载体对被忽视的寄生虫病的免疫活性。
方法：对于审查，Pubmed,Embase,和丁香花数据库使用描述符疫苗，寄生虫,和脂质体。采用以下纳入标准：体内和体外实验文章。作为排除标准：书籍章节，社论,在数据库搜索过程中发现的文献综述和重复文章。
结果：共鉴定出226篇文章，从中选出34人进行审查。确定的主要疾病包括牛巴贝虫，溶组织内阿米巴,巴西利什曼原虫,多诺瓦尼利什曼原虫,利什曼尼亚大调,利什曼原虫,恶性疟原虫,Chabaudi疟原虫,Chabaudi疟原虫,约氏疟原虫,弓形虫和克氏锥虫。细胞因子如GM-CSF的升高，MCP-1,INF-γ,TNF-α,在关于寄生虫病评价的研究中观察到IL-2、IL-4、IL-5、IL-6、IL-10、IL-12和IL-17。此外，在这些研究中,细胞因子如IL-4,IL-10和TGF-β随着疫苗系统的施用而减少.
结论：因此，脂质体纳米疫苗系统的给药可以通过调节患者的免疫学谱来有效改善患者的临床状况。
方法：对于审查，Pubmed,Embase,和丁香花数据库使用描述符疫苗，寄生虫,和脂质体。采用以下纳入标准：体内和体外实验文章。作为排除标准：书籍章节，社论,在数据库搜索过程中发现的文献综述和重复文章。
结果：共鉴定出226篇文章，从中选出34人进行审查。确定的主要疾病包括牛巴贝虫，溶组织内阿米巴,巴西利什曼原虫,多诺瓦尼利什曼原虫,利什曼尼亚大调,利什曼原虫,恶性疟原虫,Chabaudi疟原虫,Chabaudi疟原虫,约氏疟原虫,弓形虫和克氏锥虫。细胞因子如GM-CSF的升高，MCP-1,INF-γ,TNF-α,在关于寄生虫病评价的研究中观察到IL-2、IL-4、IL-5、IL-6、IL-10、IL-12和IL-17。此外，在这些研究中,细胞因子如IL-4,IL-10和TGF-β随着疫苗系统的施用而减少.
结论：因此，脂质体纳米疫苗系统的给药可以通过调节患者的免疫学谱来有效改善患者的临床状况。
